Postbundling Discontinuation in ESA Use at Hematocrit >36 percent Relative to Hematocrit ≤36 percent, by Gender, Age, Race, and Presence of Hypertension, Congestive Heart Failure, and DiabetesNotes. Each point estimate shown in the figure represents the difference in ESA use at hematocrit >36 percent relative to ESA use in patients with hematocrit ≤36 percent. Estimates shown in figure are regression-adjusted for age, sex*, race*, insurance status, initial hemoglobin, comorbid conditions, time since beginning dialysis (vintage), BMI, and albumin. Standard errors are clustered by patient hematocrit level and provider. The vertical bars denote the 95 percent confidence intervals around the point estimate. *sex: not included in gender-specific estimates; race* not included in race-specific estimates.